Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Clinical trial NCT06504199 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06504199
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-18
- Primary completion
- 2026-12-31
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.